Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Masakazu Kawajiri, M. Mogi, N. Higaki, T. Tateishi, Y. Ohyagi, M. Horiuchi, T. Miki, J. I. Kira

研究成果: ジャーナルへの寄稿コメント/討論

15 引用 (Scopus)

抄録

Recent studies suggest that angiotensin II, a major substrate in the renin-angiotensin system, protects neurons through stimulation of its type 2 receptors. However, quite a few clinical studies of angiotensin II levels have shown their relation to disease severity in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Aims of the study - To clarify the significance of angiotensin II in ALS. Methods - We assayed angiotensin II concentrations in cerebrospinal fluid (CSF) samples from 23 patients with ALS, nine patients with spinocerebellar degeneration (SCD) and 24 control individuals. We evaluated the disability levels of patients with ALS using the Revised ALS Functional Rating Scale (ALSFRS-R) and calculated the disease progression rate (DPR). Results - CSF angiotensin II levels were significantly lower in the ALS group compared with that in the control group (P = 0.00864), and showed a significant positive correlation with scores on the ALSFRS-R, and a significant negative correlation with the DPR. Conclusions - In the present study, we reveal for the first time that angiotensin II levels in the CSF from patients with ALS are significantly reduced and significantly associated with disease severity and progression rate. These findings suggest that reduced levels of intrathecal angiotensin II may play a role in ALS.

元の言語英語
ページ(範囲)341-344
ページ数4
ジャーナルActa Neurologica Scandinavica
119
発行部数5
DOI
出版物ステータス出版済み - 5 1 2009

Fingerprint

Amyotrophic Lateral Sclerosis
Angiotensin II
Cerebrospinal Fluid
Disease Progression
Spinocerebellar Degenerations
Renin-Angiotensin System
Neurodegenerative Diseases
Neurons
Control Groups

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

これを引用

Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. / Kawajiri, Masakazu; Mogi, M.; Higaki, N.; Tateishi, T.; Ohyagi, Y.; Horiuchi, M.; Miki, T.; Kira, J. I.

:: Acta Neurologica Scandinavica, 巻 119, 番号 5, 01.05.2009, p. 341-344.

研究成果: ジャーナルへの寄稿コメント/討論

Kawajiri, Masakazu ; Mogi, M. ; Higaki, N. ; Tateishi, T. ; Ohyagi, Y. ; Horiuchi, M. ; Miki, T. ; Kira, J. I. / Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. :: Acta Neurologica Scandinavica. 2009 ; 巻 119, 番号 5. pp. 341-344.
@article{2e0191862654437ca44a639423441d86,
title = "Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis",
abstract = "Recent studies suggest that angiotensin II, a major substrate in the renin-angiotensin system, protects neurons through stimulation of its type 2 receptors. However, quite a few clinical studies of angiotensin II levels have shown their relation to disease severity in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Aims of the study - To clarify the significance of angiotensin II in ALS. Methods - We assayed angiotensin II concentrations in cerebrospinal fluid (CSF) samples from 23 patients with ALS, nine patients with spinocerebellar degeneration (SCD) and 24 control individuals. We evaluated the disability levels of patients with ALS using the Revised ALS Functional Rating Scale (ALSFRS-R) and calculated the disease progression rate (DPR). Results - CSF angiotensin II levels were significantly lower in the ALS group compared with that in the control group (P = 0.00864), and showed a significant positive correlation with scores on the ALSFRS-R, and a significant negative correlation with the DPR. Conclusions - In the present study, we reveal for the first time that angiotensin II levels in the CSF from patients with ALS are significantly reduced and significantly associated with disease severity and progression rate. These findings suggest that reduced levels of intrathecal angiotensin II may play a role in ALS.",
author = "Masakazu Kawajiri and M. Mogi and N. Higaki and T. Tateishi and Y. Ohyagi and M. Horiuchi and T. Miki and Kira, {J. I.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1111/j.1600-0404.2008.01099.x",
language = "English",
volume = "119",
pages = "341--344",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

AU - Kawajiri, Masakazu

AU - Mogi, M.

AU - Higaki, N.

AU - Tateishi, T.

AU - Ohyagi, Y.

AU - Horiuchi, M.

AU - Miki, T.

AU - Kira, J. I.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Recent studies suggest that angiotensin II, a major substrate in the renin-angiotensin system, protects neurons through stimulation of its type 2 receptors. However, quite a few clinical studies of angiotensin II levels have shown their relation to disease severity in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Aims of the study - To clarify the significance of angiotensin II in ALS. Methods - We assayed angiotensin II concentrations in cerebrospinal fluid (CSF) samples from 23 patients with ALS, nine patients with spinocerebellar degeneration (SCD) and 24 control individuals. We evaluated the disability levels of patients with ALS using the Revised ALS Functional Rating Scale (ALSFRS-R) and calculated the disease progression rate (DPR). Results - CSF angiotensin II levels were significantly lower in the ALS group compared with that in the control group (P = 0.00864), and showed a significant positive correlation with scores on the ALSFRS-R, and a significant negative correlation with the DPR. Conclusions - In the present study, we reveal for the first time that angiotensin II levels in the CSF from patients with ALS are significantly reduced and significantly associated with disease severity and progression rate. These findings suggest that reduced levels of intrathecal angiotensin II may play a role in ALS.

AB - Recent studies suggest that angiotensin II, a major substrate in the renin-angiotensin system, protects neurons through stimulation of its type 2 receptors. However, quite a few clinical studies of angiotensin II levels have shown their relation to disease severity in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Aims of the study - To clarify the significance of angiotensin II in ALS. Methods - We assayed angiotensin II concentrations in cerebrospinal fluid (CSF) samples from 23 patients with ALS, nine patients with spinocerebellar degeneration (SCD) and 24 control individuals. We evaluated the disability levels of patients with ALS using the Revised ALS Functional Rating Scale (ALSFRS-R) and calculated the disease progression rate (DPR). Results - CSF angiotensin II levels were significantly lower in the ALS group compared with that in the control group (P = 0.00864), and showed a significant positive correlation with scores on the ALSFRS-R, and a significant negative correlation with the DPR. Conclusions - In the present study, we reveal for the first time that angiotensin II levels in the CSF from patients with ALS are significantly reduced and significantly associated with disease severity and progression rate. These findings suggest that reduced levels of intrathecal angiotensin II may play a role in ALS.

UR - http://www.scopus.com/inward/record.url?scp=64549123960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549123960&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2008.01099.x

DO - 10.1111/j.1600-0404.2008.01099.x

M3 - Comment/debate

C2 - 18798831

AN - SCOPUS:64549123960

VL - 119

SP - 341

EP - 344

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 5

ER -